Sami Diab
Intermountain Healthcare · 98 works · 5,322 citations · h-index 29
Top works
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G 1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinomas
- Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
- Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.
- A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
- First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
- Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
- Talazoparib in Patients with a Germline BRCA -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
- Identification of germline 185delAG BRCA1 mutations in non‐Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado
- WAF1/CIP1 protein expression in human breast tumors
- First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
- Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
- Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
- HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study
- Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer